testtargettreat.com Report : Visit Site

Technical data of the testtargettreat.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host testtargettreat.com. Currently, hosted in United States and its service provider is Amazon.com Inc. .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

test target treat - antibiotic resistance solutions & education skip to content × contact us about antimicrobial misuse and resistance consequences of antimicrobial misuse antimicrobial stewardship implementation rapid diagnostics c. difficile c-reactive protein influenza (flu) legionnaires' disease malaria mrsa pneumococcal pneumonia rsv strep a pharyngitis verotoxigenic escherichia coli (e. coli) educational resources educational monographs videos case studies c-reactive protein case study pneumonia case study influenza case study tuberculosis case study strep a pharyngitis case study webinars useful links online courses news & events contact us contact us about rapid diagnostics educational resources news & events contact us antimicrobial misuse and resistance consequences of antimicrobial misuse antimicrobial stewardship implementation close c. difficile c-reactive protein influenza (flu) legionnaires' disease malaria mrsa pneumococcal pneumonia rsv strep a pharyngitis verotoxigenic escherichia coli (e. coli) close educational monographs videos case studies c-reactive protein case study pneumonia case study influenza case study tuberculosis case study strep a pharyngitis case study webinars useful links online courses close what doesn't kill them makes them stronger. the test target treat™ initiative from alere empowers healthcare professionals to make targeted treatment decisions sooner with rapid diagnostics. learn more open up to a world of antimicrobial resistance education explore case studies explore monographs watch webinars antimicrobial resistance news new clinical practice guidelines for clostridium difficile infection in adults and children new guidelines for clostridium difficile issued by the infectious diseases society of america and the society for healthcare epidemiology of america were prompted by extensive research published since the release of the 2010 guidelines. read full article more news new respiratory infections team utilzes rapid tests to reduce both hospital stay for patients with pneumonia and unnecessary antibiotic use a new, nurse-led ‘respiratory infections team’ is delivering targeted and effective diagnosis and treatment for patients with community-acquired pneumonia leading to reduced hospital stays for the condition. read full article more news amr industry alliance produces first report on january 18th, the amr industry alliance launched its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (amr). read full article more news previous ◀︎ next ▶︎ slide 0 slide 1 slide 2 antimicrobial resistance news new clinical practice guidelines for clostridium difficile infection in adults and children new guidelines for clostridium difficile issued by the infectious diseases society of america and the society for healthcare epidemiology of america were prompted by extensive research published since the release of the 2010 guidelines. read full article more news antimicrobial resistance news new respiratory infections team utilzes rapid tests to reduce both hospital stay for patients with pneumonia and unnecessary antibiotic use a new, nurse-led ‘respiratory infections team’ is delivering targeted and effective diagnosis and treatment for patients with community-acquired pneumonia leading to reduced hospital stays for the condition. read full article more news antimicrobial resistance news amr industry alliance produces first report on january 18th, the amr industry alliance launched its first report that shows the commitment of the life sciences industry to tackle the public health threat of antimicrobial resistance (amr). read full article more news previous ◀︎ next ▶︎ slide 0 slide 1 slide 2 rapid diagnostics see how new, rapid and reliable point of care technologies and tests can help you make prudent decisions around the use of antibiotics. discover our tests sign up for our test target treat newsletter to receive valuable updates. sign up follow us for the latest on antimicrobial resistance and rapid diagnostics. × about antimicrobial misuse and resistance consequences of antimicrobial misuse antimicrobial stewardship implementation rapid diagnostics c. difficile c-reactive protein influenza (flu) legionnaires' disease malaria mrsa pneumococcal pneumonia rsv strep a pharyngitis verotoxigenic escherichia coli (e. coli) educational resources educational monographs videos case studies webinars useful links online courses news & events contact us about antimicrobial misuse and resistance consequences of antimicrobial misuse antimicrobial stewardship implementation rapid diagnostics c. difficile c-reactive protein influenza (flu) legionnaires' disease malaria mrsa pneumococcal pneumonia rsv strep a pharyngitis verotoxigenic escherichia coli (e. coli) educational resources educational monographs videos case studies webinars useful links online courses news & events contact us © 2018 alere. all rights reserved. the alere logo, alere, acceava, afinion, binaxnow, clearview, nycocard and test target treat are trademarks of the alere group of companies. c. diff quik chek complete, shiga toxin quik chek , the techlab logo and techlab are trademarks of techlab, inc. under license. all other trademarks referenced are trademarks of their respective owners. products available in select markets only. this website is governed by applicable u.s. laws and governmental regulations. the products and information contained herewith may not be accessible in all countries, and alere takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. your use of this website and the information contained herein is subject to our website terms and conditions and privacy policy . the companies, websites, products and services, and brands referenced and linked to from this website are not sponsored or endorsed by, or otherwise affiliated with, alere or testtargettreat.com. gdpr statement . the third-party trademarks, products and services referenced and linked to from this website are included for informational purposes only, and have not been tested or approved by alere or testtargettreat.com. neither alere nor testtargettreat.com make any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof. see the website terms and conditions for additional details. for full functionality of this site it is necessary to enable javascript. here are the instructions how to enable javascript in your web browser .

URL analysis for testtargettreat.com

https://www.testtargettreat.com/en/home/news-events/new-clinical-practice-guidelines-c-diff.html
https://www.testtargettreat.com/en/home/educational-resources/case-studies/influenza-case-study.html
https://www.testtargettreat.com/en/home/educational-resources/case-studies/pneumonia-case-study.html
https://www.testtargettreat.com/en/home/educational-resources/videos.html
https://www.testtargettreat.com/en/home/rapid-diagnostics/legionnaires-disease.html
https://www.testtargettreat.com/en/home/about/antimicrobial-misuse-resistance.html
https://www.testtargettreat.com/en/home/educational-resources/online-courses.html
https://www.testtargettreat.com/en/home/news-events/new-respiratory-infections-team.html
https://www.testtargettreat.com/en/home/rapid-diagnostics/c-reactive-protein.html
https://www.testtargettreat.com/en/home/news-events.html
https://www.testtargettreat.com/en/home/educational-resources/case-studies.html
https://www.testtargettreat.com/en/home/news-events/amr-industry-alliance.html
https://www.testtargettreat.com/#maincontent
https://www.testtargettreat.com/en/home/educational-resources/useful-links.html
https://www.testtargettreat.com/en/home/rapid-diagnostics/influenza-flu.html

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: TESTTARGETTREAT.COM
Registry Domain ID: 1748290407_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corporatedomains.com
Registrar URL: http://www.cscglobal.com/global/web/csc/digital-brand-services.html
Updated Date: 2017-09-23T05:03:43Z
Creation Date: 2012-09-28T00:43:36Z
Registry Expiry Date: 2019-09-28T00:43:36Z
Registrar: CSC Corporate Domains, Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 8887802723
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS1.CSCDNS.NET
Name Server: DNS2.CSCDNS.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-07-05T12:02:50Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR CSC Corporate Domains, Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =testtargettreat.com

  PORT 43

  TYPE domain

DOMAIN

  NAME testtargettreat.com

  CHANGED 2017-09-23

  CREATED 2012-09-28

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  DNS1.CSCDNS.NET 209.112.114.33

  DNS2.CSCDNS.NET 69.36.145.33

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .